Triumeq PD (abacavir/dolutegravir/lamivudine) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:			
Instructions: Please fill out all important for the review (e.g., this form is Protected Health I	chart notes or lab data, to sup				
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE ID NUMBER:					
MALE FEMALE HEIGHT OF THE PRESCRIF FOLLOWING LINK: PRIMETHERAPEUTICS.COM/PATIENT'S AUTHORIZED REPRAUTHORIZED REPRAUTHORIZED REPRAUTHORIZED REPRAUTHORIZED REPRESENTATIVE	BER, YOU WILL NEED TO SUBMIT A PHI DISCLONOPP ESENTATIVE (IF APPLICABLE):	SURE AUTHORIZATION FOR	M WITH THIS REQI	UEST WHICH CAN BE FOUND AT THE	
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:		L			
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
		I			
MEDICATION OR MEDICAL I	DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILL	S:	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPE	CIFIC DATES):				

Continued on next page.



Triumeq PD (abacavir/dolutegravir/lamivudine) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 🔲 NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
□ HIV				
□ Other diagnosis:	ICD-10			
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINICA	AL INFORMATION TO SUPPORT A		
Clinical Information:				
Is the drug going to be used in conjunc	tion with a clinical trial? Yes No			
Is patient an infant or child weighing 10 – 24 kg? □ Yes □ No				
Can patient swallow tablets or capsules? □ Yes □ No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
*Please note: Not all drugs/diagnoses a information is received.	are covered on all plans. This request ma	y be denied unless all required		
the Health Plan, insurer, Medical Group	provided is true and accurate to the best or its designees may perform a routine uracy of the information reported on thi	audit and request the medical		
Prescriber Signature or Electronic I.D.	Verification:	Date:		
you are not the intended recipient, you are here	ompanying this transmission contain confidential by notified that any disclosure, copying, distribut have received this information in error, please no se documents.	tion, or action taken in reliance on the contents		

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

